Giuseppe Scalabrino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giuseppe Scalabrino has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Daniela Veber
Department of Biomedical Sciences, Laboratory of Neuropathology, University of Milan, Via Mangiagalli 31, 20133 Milano, Italy
21 shared publications- Elena Mutti
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
12 shared publications Giovanni Tredici
Department of Translational Medicine and Surgery, University of Milano-Bicocca, 20052 Monza, Italy
5 shared publicationsFrancesca R. Buccellato
Institute of General Pathology and Center of Excellence on Neurodegenerative Diseases, University of Milan, Milan, Italy
4 shared publications- Elena Gammella
Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy
3 shared publications - Lorenza Tacchini
Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy
3 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by MDPI AG in Preprints.org
More Studies of the Deranged Myelinotrophic Factors in Multiple Sclerosis Central Nervous System Are Needed to Clarify Their Pathogenic Meaning
Many molecules (mainly growth factors and/or cytokines) are produced by human central nervous system (CNS) cells and may positively or negatively influence oligodendrogenesis, proliferation, and the migration of oligodendrocyte precursor cells (OPCs). Multiple sclerosis (MS) leads to the destruction of CNS myelin sheaths and myelin-producing oligodendrocytes (ODCs). This review considers the few published studies of platelet-derived growth factor (PDGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and ciliary-neurotrophic factor (CNTF) in cerebrospinal fluid and/or post-mortem CNS samples which, like previously reviewed studies of epidermal growth factor (EGF), have shown deranged levels in MS, and also considers the abnormal levels of Nuclear Factor kappa-light-chain-enhancer of activated B cells and some microRNAs in MS CNS. The derangements of all of these molecules in MS CNS surely hinder ODC differentiation, proliferation, and migration, and ultimately they contribute to remyelination failure. Despite the differences between MS and experimental autoimmune encephalomyelitis (EAE), it is also worth noting that the individual administration of PDGF, BDNF, CTNF, and EGF prevents the onset and/or “cures” EAE in mice, and so, together with findings concerning other aspects of MS, the results of the reviewed studies seem to support the idea that MS demyelination is a consequence of oligodendrocytopathy followed by an autoimmunity reaction.
- 27 November 2025
- Published by MDPI AG in Preprints.org
Open AccessMore Studies of the Deranged Myelinotrophic Factors in Multiple Sclerosis Central Nervous System Are Needed to Clarify Their Pathogenic Meaning
Many molecules (mainly growth factors and/or cytokines) are produced by human central nervous system (CNS) cells and may positively or negatively influence oligodendrogenesis, proliferation, and the migration of oligodendrocyte precursor cells (OPCs). Multiple sclerosis (MS) leads to the destruction of CNS myelin sheaths and myelin-producing oligodendrocytes (ODCs). This review considers the few published studies of platelet-derived growth factor (PDGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and ciliary-neurotrophic factor (CNTF) in cerebrospinal fluid and/or post-mortem CNS samples which, like previously reviewed studies of epidermal growth factor (EGF), have shown deranged levels in MS, and also considers the abnormal levels of Nuclear Factor kappa-light-chain-enhancer of activated B cells and some microRNAs in MS CNS. The derangements of all of these molecules in MS CNS surely hinder ODC differentiation, proliferation, and migration, and ultimately they contribute to remyelination failure. Despite the differences between MS and experimental autoimmune encephalomyelitis (EAE), it is also worth noting that the individual administration of PDGF, BDNF, CTNF, and EGF prevents the onset and/or “cures” EAE in mice, and so, together with findings concerning other aspects of MS, the results of the reviewed studies seem to support the idea that MS demyelination is a consequence of oligodendrocytopathy followed by an autoimmunity reaction.
- Open Access
- 30 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 815
Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure
The pathogenesis of multiple sclerosis (MS) remains enigmatic and controversial. Myelin sheaths in the central nervous system (CNS) insulate axons and allow saltatory nerve conduction. MS brings about the destruction of myelin sheaths and the myelin-producing oligodendrocytes (ODCs). The conundrum of remyelination failure is, therefore, crucial in MS. In this review, the roles of epidermal growth factor (EGF), normal prions, and cobalamin in CNS myelinogenesis are briefly summarized. Thereafter, some findings of other authors and ourselves on MS and MS-like models are recapitulated, because they have shown that: (a) EGF is significantly decreased in the CNS of living or deceased MS patients; (b) its repeated administration to mice in various MS-models prevents demyelination and inflammatory reaction; (c) as was the case for EGF, normal prion levels are decreased in the MS CNS, with a strong correspondence between liquid and tissue levels; and (d) MS cobalamin levels are increased in the cerebrospinal fluid, but decreased in the spinal cord. In fact, no remyelination can occur in MS if these molecules (essential for any form of CNS myelination) are lacking. Lastly, other non-immunological MS abnormalities are reviewed. Together, these results have led to a critical reassessment of MS pathogenesis, partly because EGF has little or no role in immunology.
- 30 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 815
Open AccessNewly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure
The pathogenesis of multiple sclerosis (MS) remains enigmatic and controversial. Myelin sheaths in the central nervous system (CNS) insulate axons and allow saltatory nerve conduction. MS brings about the destruction of myelin sheaths and the myelin-producing oligodendrocytes (ODCs). The conundrum of remyelination failure is, therefore, crucial in MS. In this review, the roles of epidermal growth factor (EGF), normal prions, and cobalamin in CNS myelinogenesis are briefly summarized. Thereafter, some findings of other authors and ourselves on MS and MS-like models are recapitulated, because they have shown that: (a) EGF is significantly decreased in the CNS of living or deceased MS patients; (b) its repeated administration to mice in various MS-models prevents demyelination and inflammatory reaction; (c) as was the case for EGF, normal prion levels are decreased in the MS CNS, with a strong correspondence between liquid and tissue levels; and (d) MS cobalamin levels are increased in the cerebrospinal fluid, but decreased in the spinal cord. In fact, no remyelination can occur in MS if these molecules (essential for any form of CNS myelination) are lacking. Lastly, other non-immunological MS abnormalities are reviewed. Together, these results have led to a critical reassessment of MS pathogenesis, partly because EGF has little or no role in immunology.
- Open Access
- 26 November 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
New Epidermal-Growth-Factor-Related Insights Into the Pathogenesis of Multiple Sclerosis: Is It Also Epistemology?
Recent findings showing that epidermal growth factor (EGF) is significantly decreased in the cerebrospinal fluid (CSF) and spinal cord (SC) of living or deceased multiple sclerosis (MS) patients, and that its repeated administration to rodents with chemically- or virally-induced demyelination of the central nervous system (CNS) or experimental allergic encephalomyelitis (EAE) prevents demyelination and inflammatory reactions in the CNS, have led to a critical reassessment of the MS pathogenesis, partly because EGF is considered to have little or no role in immunology. EGF is the only myelinotrophic factor that has been tested in the CSF and spinal cord of MS patients, and it has been shown there is a good correspondence between liquid and tissue levels. This review: (a) briefly summarises the positive EGF effects on neural stem cells, oligodendrocyte cell lineage, and astrocytes in order to explain, at least in part, the biological basis of the myelin loss and remyelination failure in MS; and (b) after a short analysis of the evolution of the principle of cause-effect in the history of Western philosophy, highlights the lack of any experimental immune-, toxin-, or virus-mediated model that precisely reproduces the histopathological features and “clinical” symptoms of MS, thus underlining the inapplicability of Claude Bernard's crucial sequence of “observation, hypothesis, and hypothesis testing.” This is followed by a discussion of most of the putative non-immunologically-linked points of MS pathogenesis (abnormalities in myelinotrophic factor CSF levels, oligodendrocytes (ODCs), astrocytes, extracellular matrix, and epigenetics) on the basis of Popper's falsification principle, and the suggestion that autoimmunity and phologosis reactions (surely the most devasting consequences of the disease) are probably the last links in a chain of events that trigger the reactions. As it is likely that there is a lack of other myelinotrophic growth factors because myelinogenesis is controlled by various CNS and extra-CNS growth factors and other molecules within and outside ODCs, further studies are needed to investigate the role of non-immunological molecules at the time of the onset of the disease. In the words of Galilei, the human mind should be prepared to understand what nature has created.
- 26 November 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessNew Epidermal-Growth-Factor-Related Insights Into the Pathogenesis of Multiple Sclerosis: Is It Also Epistemology?
Recent findings showing that epidermal growth factor (EGF) is significantly decreased in the cerebrospinal fluid (CSF) and spinal cord (SC) of living or deceased multiple sclerosis (MS) patients, and that its repeated administration to rodents with chemically- or virally-induced demyelination of the central nervous system (CNS) or experimental allergic encephalomyelitis (EAE) prevents demyelination and inflammatory reactions in the CNS, have led to a critical reassessment of the MS pathogenesis, partly because EGF is considered to have little or no role in immunology. EGF is the only myelinotrophic factor that has been tested in the CSF and spinal cord of MS patients, and it has been shown there is a good correspondence between liquid and tissue levels. This review: (a) briefly summarises the positive EGF effects on neural stem cells, oligodendrocyte cell lineage, and astrocytes in order to explain, at least in part, the biological basis of the myelin loss and remyelination failure in MS; and (b) after a short analysis of the evolution of the principle of cause-effect in the history of Western philosophy, highlights the lack of any experimental immune-, toxin-, or virus-mediated model that precisely reproduces the histopathological features and “clinical” symptoms of MS, thus underlining the inapplicability of Claude Bernard's crucial sequence of “observation, hypothesis, and hypothesis testing.” This is followed by a discussion of most of the putative non-immunologically-linked points of MS pathogenesis (abnormalities in myelinotrophic factor CSF levels, oligodendrocytes (ODCs), astrocytes, extracellular matrix, and epigenetics) on the basis of Popper's falsification principle, and the suggestion that autoimmunity and phologosis reactions (surely the most devasting consequences of the disease) are probably the last links in a chain of events that trigger the reactions. As it is likely that there is a lack of other myelinotrophic growth factors because myelinogenesis is controlled by various CNS and extra-CNS growth factors and other molecules within and outside ODCs, further studies are needed to investigate the role of non-immunological molecules at the time of the onset of the disease. In the words of Galilei, the human mind should be prepared to understand what nature has created.
- Open Access
- 5 November 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 42 (4) , 891-916
Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview
This article reviews the wealth of papers dealing with the different effects of epidermal growth factor (EGF) on oligodendrocytes, astrocytes, neurons, and neural stem cells (NSCs). EGF induces the in vitro and in vivo proliferation of NSCs, their migration, and their differentiation towards the neuroglial cell line. It interacts with extracellular matrix components. NSCs are distributed in different CNS areas, serve as a reservoir of multipotent cells, and may be increased during CNS demyelinating diseases. EGF has pleiotropic differentiative and proliferative effects on the main CNS cell types, particularly oligodendrocytes and their precursors, and astrocytes. EGF mediates the in vivo myelinotrophic effect of cobalamin on the CNS, and modulates the synthesis and levels of CNS normal prions (PrPCs), both of which are indispensable for myelinogenesis and myelin maintenance. EGF levels are significantly lower in the cerebrospinal fluid and spinal cord of patients with multiple sclerosis (MS), which probably explains remyelination failure, also because of the EGF marginal role in immunology. When repeatedly administered, EGF protects mouse spinal cord from demyelination in various experimental models of autoimmune encephalomyelitis. It would be worth further investigating the role of EGF in the pathogenesis of MS because of its multifarious effects.
- 5 November 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 42 (4) , 891-916
Open AccessEpidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview
This article reviews the wealth of papers dealing with the different effects of epidermal growth factor (EGF) on oligodendrocytes, astrocytes, neurons, and neural stem cells (NSCs). EGF induces the in vitro and in vivo proliferation of NSCs, their migration, and their differentiation towards the neuroglial cell line. It interacts with extracellular matrix components. NSCs are distributed in different CNS areas, serve as a reservoir of multipotent cells, and may be increased during CNS demyelinating diseases. EGF has pleiotropic differentiative and proliferative effects on the main CNS cell types, particularly oligodendrocytes and their precursors, and astrocytes. EGF mediates the in vivo myelinotrophic effect of cobalamin on the CNS, and modulates the synthesis and levels of CNS normal prions (PrPCs), both of which are indispensable for myelinogenesis and myelin maintenance. EGF levels are significantly lower in the cerebrospinal fluid and spinal cord of patients with multiple sclerosis (MS), which probably explains remyelination failure, also because of the EGF marginal role in immunology. When repeatedly administered, EGF protects mouse spinal cord from demyelination in various experimental models of autoimmune encephalomyelitis. It would be worth further investigating the role of EGF in the pathogenesis of MS because of its multifarious effects.
- 29 September 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 359 (1-2) , 396-403
Are PrPCs involved in some human myelin diseases? Relating experimental studies to human pathology
- 29 September 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 359 (1-2) , 396-403
Are PrPCs involved in some human myelin diseases? Relating experimental studies to human pathology
- 1 July 2015
- Published by Elsevier in Neuroscience
- Vol. 298, 293-301
Low levels of cobalamin, epidermal growth factor, and normal prions in multiple sclerosis spinal cord
- 1 July 2015
- Published by Elsevier in Neuroscience
- Vol. 298, 293-301
Low levels of cobalamin, epidermal growth factor, and normal prions in multiple sclerosis spinal cord
- 30 December 2014
- Published by PAGEPress Publications in Istituto Lombardo - Accademia di Scienze e Lettere - Rendiconti di Scienze
VITAMIN B12 AND NORMAL PRIONS: TWO FIELDS APPARENTLY SO FAR, BUT IN REALITY SO NEAR
Cobalamin (Cbl) deficiency causes an imbalance in some cytokines and growth factors in the central nervous system and peripheral nervous system of the rat, and in the serum and cerebrospinal fluid (CSF) of adult Cbl-deficient (Cbl-D) patients. We hypothesized that an imbalance in normal prion (PrPC) levels and/or synthesis might be involved in the pathogenesis of Cbl-D neuropathy. Using different appropriate enzyme-linked immunosorbent assays (ELISAs), we determined the levels of Cbl, tumour necrosis factor-a, epidermal growth factor, and PrPC in spinal cord (SC) and CSF of Cbl-D rats treated or not with different molecules; in serum, CSF from Cbl-D or multiple sclerosis (MS) patients; and in post-mortem SC samples taken from MS patients and control patients. We have demonstrated that: (i) Cbl deficiency induces excess PrPC regions (particularly octapeptide repeated (OR) region) in rat SC; (ii) the SC increase is mediated by a local Cbl deficiency-induced excess of tumour necrosis factor- a; and (iii) CSF and serum PrPC concentrations in Cbl-D patients are significantly higher than in controls. CSF PrPC concentrations are significantly lower in MS patients than neurological controls. The Cbl, EGF, and PrPC levels were significantly decreased in post-mortem MS SCs in comparison with controls
- 30 December 2014
- Published by PAGEPress Publications in Istituto Lombardo - Accademia di Scienze e Lettere - Rendiconti di Scienze
VITAMIN B12 AND NORMAL PRIONS: TWO FIELDS APPARENTLY SO FAR, BUT IN REALITY SO NEAR
Cobalamin (Cbl) deficiency causes an imbalance in some cytokines and growth factors in the central nervous system and peripheral nervous system of the rat, and in the serum and cerebrospinal fluid (CSF) of adult Cbl-deficient (Cbl-D) patients. We hypothesized that an imbalance in normal prion (PrPC) levels and/or synthesis might be involved in the pathogenesis of Cbl-D neuropathy. Using different appropriate enzyme-linked immunosorbent assays (ELISAs), we determined the levels of Cbl, tumour necrosis factor-a, epidermal growth factor, and PrPC in spinal cord (SC) and CSF of Cbl-D rats treated or not with different molecules; in serum, CSF from Cbl-D or multiple sclerosis (MS) patients; and in post-mortem SC samples taken from MS patients and control patients. We have demonstrated that: (i) Cbl deficiency induces excess PrPC regions (particularly octapeptide repeated (OR) region) in rat SC; (ii) the SC increase is mediated by a local Cbl deficiency-induced excess of tumour necrosis factor- a; and (iii) CSF and serum PrPC concentrations in Cbl-D patients are significantly higher than in controls. CSF PrPC concentrations are significantly lower in MS patients than neurological controls. The Cbl, EGF, and PrPC levels were significantly decreased in post-mortem MS SCs in comparison with controls
- 1 October 2014
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 55, 232-241
Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system
- 1 October 2014
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 55, 232-241
Relationships between cobalamin, epidermal growth factor, and normal prions in the myelin maintenance of central nervous system
- 20 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (8) , 1451-1460
Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis
Cobalamin (Cbl) deficiency causes an imbalance in some cytokines and growth factors in the central nervous system and peripheral nervous system (PNS) of the rat, and in the serum and cerebrospinal fluid (CSF) of adult Cbl-deficient (Cbl-D) patients. It is conceivable that this imbalance triggers subsequent cellular events. We hypothesized that an imbalance in normal prion (PrPC) levels and/or synthesis might be involved in the pathogenesis of Cbl-D neuropathy, and demonstrated that: (1) Cbl deficiency induces excess PrPC in rat spinal cord (SC) and PNS, concomitantly with myelin damage and PNS electrophysiological abnormalities; (2) the SC increase is mediated by a local Cbl deficiency-induced excess of tumor necrosis factor-α; (3) myelinotrophic Cbl and epidermal growth factor upregulate PrPC-mRNA levels in rat SC; (4) treatment with anti-PrPC octapeptide repeat region antibodies normalizes the ultrastructure of the Cbl-D rat SC and PNS myelins, and the PNS electrophysiological abnormalities, without modifying their Cbl-D status; (5) PrPC administration to otherwise normal rats causes SC and PNS myelin lesions and PNS electrophysiological abnormalities, similar to those of Cbl-D neuropathy; (6) CSF and serum PrPC concentrations in Cbl-D patients are significantly higher than in controls; and (7) these concentrations significantly correlate with their CSF and serum Cbl concentrations. CSF PrPC concentrations are significantly lower in patients with multiple sclerosis (MS) than neurological controls, but serum PrPC concentrations in patients with non-Cbl-D anemias and CSF PrPC concentrations in patients with non-myelin-damaging neurological diseases are normal.
- 20 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (8) , 1451-1460
Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis
Cobalamin (Cbl) deficiency causes an imbalance in some cytokines and growth factors in the central nervous system and peripheral nervous system (PNS) of the rat, and in the serum and cerebrospinal fluid (CSF) of adult Cbl-deficient (Cbl-D) patients. It is conceivable that this imbalance triggers subsequent cellular events. We hypothesized that an imbalance in normal prion (PrPC) levels and/or synthesis might be involved in the pathogenesis of Cbl-D neuropathy, and demonstrated that: (1) Cbl deficiency induces excess PrPC in rat spinal cord (SC) and PNS, concomitantly with myelin damage and PNS electrophysiological abnormalities; (2) the SC increase is mediated by a local Cbl deficiency-induced excess of tumor necrosis factor-α; (3) myelinotrophic Cbl and epidermal growth factor upregulate PrPC-mRNA levels in rat SC; (4) treatment with anti-PrPC octapeptide repeat region antibodies normalizes the ultrastructure of the Cbl-D rat SC and PNS myelins, and the PNS electrophysiological abnormalities, without modifying their Cbl-D status; (5) PrPC administration to otherwise normal rats causes SC and PNS myelin lesions and PNS electrophysiological abnormalities, similar to those of Cbl-D neuropathy; (6) CSF and serum PrPC concentrations in Cbl-D patients are significantly higher than in controls; and (7) these concentrations significantly correlate with their CSF and serum Cbl concentrations. CSF PrPC concentrations are significantly lower in patients with multiple sclerosis (MS) than neurological controls, but serum PrPC concentrations in patients with non-Cbl-D anemias and CSF PrPC concentrations in patients with non-myelin-damaging neurological diseases are normal.